Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...

In this interview Prof. Dr. Kristina Kusche-Vihrog speaks about the nanomechanics of living cells and their implications for ...

In this manuscript, Li and colleagues study the fate of endothelial cells in a mouse model of ischemic stroke. Using genetic lineage tracing approaches, they found that endothelial cells give rise to ...

Aurion is developing AURN001, a clinical-stage allogeneic cell therapy asset, for corneal edema secondary to corneal ...

Patients with Fuchs endothelial corneal dystrophy with particular genetic markers are at higher risk for surgery and vision loss.

jichi.ac.jp Objectives To develop an in vitro model for studying the biological effect of complex-flow stress on endothelial cells in three-dimensional (3D) patient-specific vascular geometry.

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

A new review explores how TMAO, a gut-derived metabolite from red meat and other foods, contributes to heart and brain ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a ...

Alcon said that its majority stake means that Aurion will have "broader R&D, regulatory, medical ophthalmic, and commercial ...

One event in particular caught the CDC's attention. In October 2024, an organ procurement organization in Texas notified CDC ...